Metalgial (Metamizole Sodium)

Metamizole works by inhibiting cyclooxygenase enzymes, which reduces the production of prostaglandins—chemical mediators that cause pain and fever. While the precise analgesic pathway is not fully defined, the decrease in prostaglandin synthesis underlies its pain‑relieving and antipyretic effects.

The dosage of Metalgial is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, age, and renal or hepatic function. Healthcare professionals set the appropriate dose and dosing interval according to current clinical guidelines and individual patient needs.

Safety data for Metalgial in pregnancy and lactation are limited, and the drug is generally not recommended unless the potential benefit justifies the possible risk to the fetus or infant. Physicians should evaluate each case individually and discuss alternatives when appropriate.

To request Metalgial, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with traditional NSAIDs, Metalgial offers potent analgesic and antipyretic effects with a different safety profile, notably a lower risk of gastrointestinal ulceration but a higher concern for blood‑cell disorders such as agranulocytosis. Clinicians choose it when strong pain control is needed and NSAID‑related GI risk is a priority.

Metalgial should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Metalgial is taken orally, usually with a full glass of water. It can be administered with or without food, but patients who experience stomach upset may benefit from taking it with meals. The exact administration schedule is defined by the prescribing healthcare professional.

The most serious adverse reactions include agranulocytosis, which is a potentially life‑threatening drop in white blood cells, and severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome. Prompt medical evaluation is essential if signs of infection, rash, or breathing difficulties develop.

Metalgial is contraindicated in patients with known hypersensitivity to Metamizole or other pyrazolones, those with a history of agranulocytosis or severe blood dyscrasias, and individuals with severe hepatic or renal impairment where the drug cannot be safely cleared.